It is disclosed a pharmaceutical and/or phytosanitary composition comprising an aqueous extract of Chelidonium majus root and an acceptable pharmaceutical or phytosanitary excipient for the prevention or treatment of nail infections. The composition may further comprise an aqueous extract of Thuja occidentalis leaf; and from about 1 to 5% of at least one natural phenolic compound. The composition is efficient in the treatment of plant infection (mildew fungus, blight fungus, etc); the treatment of intumescence of a plant; the treatment of potatoes (powdery or common scab, Rhizoctonia, etc), and also allows a higher crop yield: without the use of a chemical fungicide. The composition also allows rapid treatment of fungus infection of nails.

It is disclosed a pharmaceutical and/or phytosanitary composition comprising an aqueous extract of Chelidonium majus root and an acceptable pharmaceutical or phytosanitary excipient for the prevention or treatment of nail infections. The composition may further comprise an aqueous extract of Thuja occidentalis leaf; and from about 1 to 5% of at least one natural phenolic compound. The composition is efficient in the treatment of plant infection (mildew fungus, blight fungus, etc); the treatment of intumescence of a plant; the treatment of potatoes (powdery or common scab, Rhizoctonia, etc), and also allows a higher crop yield: without the use of a chemical fungicide. The composition also allows rapid treatment of fungus infection of nails.

An article of manufacture according to the present invention comprises a composition including a glycosaminoglycan, a local anesthetic, and a buffer packaged in a syringe or vial constructed from either glass or a plastic selected from the group consisting of cyclic olefin polymer, cyclic olefin copolymer, or high density non-nucleated polypropylene. The composition has unexpectedly improved stability on storage. The composition can be formulated for treatment of a urinary tract disease or condition, such as interstitial cystitis, also known as bladder pain syndrome or hypersensitive bladder syndrome.

An article of manufacture according to the present invention comprises a composition including a glycosaminoglycan, a local anesthetic, and a buffer packaged in a syringe or vial constructed from either glass or a plastic selected from the group consisting of cyclic olefin polymer, cyclic olefin copolymer, or high density non-nucleated polypropylene. The composition has unexpectedly improved stability on storage. The composition can be formulated for treatment of a urinary tract disease or condition, such as interstitial cystitis, also known as bladder pain syndrome or hypersensitive bladder syndrome.

The present invention relates to compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

A pharmaceutical composition or a health functional food including a macrolide compound, a method of preparing the same, and a method using the same may be used to prevent or treat Mycobacterium sp. bacterial infection, such as tuberculosis, Hansen's disease, and non-tuberculous Mycobacterium sp. bacterial infections, or symptoms related thereto.

A pharmaceutical composition or a health functional food including a macrolide compound, a method of preparing the same, and a method using the same may be used to prevent or treat Mycobacterium sp. bacterial infection, such as tuberculosis, Hansen's disease, and non-tuberculous Mycobacterium sp. bacterial infections, or symptoms related thereto.

The current invention is based on the determination that a S1P receptor modulator compound of formula (I):

##STR00001##

decreases the heart rate of a subject to which it is administered by about 5 beats/min or less daily, or about 4 beats/min or less daily, or about 3 beats/min or less daily, or about 2 beats/min or less daily, wherein the S1P receptor modulator is administered at an initial daily dosage which is substantially the same as the standard daily therapeutic dosage.

Described herein is the use of compound 1, an antifungal agent with a novel mechanism of action, in the treatment of fungal infections.

Described herein is the use of compound 1, an antifungal agent with a novel mechanism of action, in the treatment of fungal infections.